Early brain‐penetrant immunotherapy reverses interferon signature and improves motor outcome in a case of ADAR1 ‐related Aicardi‐Goutières syndrome
Clinical & Translational Immunology · 2026-07 · 15 (7)
DOI: 10.1002/cti2.70113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 28.06.2026. Verfasst von Russell C Dale und 13 weiteren Autor:innen. Beteiligte Einrichtung: Kids Neuroscience Centre, Faculty of Medicine and Health, The Children's Hospital at Westmead University of Sydney Sydney NSW Australia. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Aicardi‐Goutières syndrome (AGS) is a genetic interferonopathy resulting from defects in nucleic acid metabolism and subsequent enhanced type I interferon signalling. We report how an expedited genomic diagnosis in conjunction with natural history data can enable a long‐term brain‐penetrant anti‐inflammatory regimen to optimise neurodevelopmental outcomes in genetic autoinflammatory brain disorders.
Methods
Expedited genomic testing identified compound heterozygous ADAR1 mutations. Published natural history data from 33 patients with biallelic ADAR1 mutations reported severe disability (GMFCS V) or death in 79%. To reduce neuroinflammation, we commenced a long‐term pulsed oral dexamethasone protocol (20 mg/m 2 for 3 days every 3 weeks) from the age of 11 months, plus ruxolitinib, a Janus Kinase (JAK) inhibitor (5 mg per day).
Results
At the age of 24 months, the patient was crawling and walking a few steps unaided, with a GMFCS level of II. Single‐cell RNA sequencing of 41 164 leukocytes, taken before and after 3 months of treatment and compared to three age matched male controls, showed a reversal of upregulated pan‐cellular interferon pathways, with most differentially expressed genes observed in monocytes. On treatment, there was statistically significant downregulation of key autoinflammatory genes, including nucleic acid sensing ( CGAS, IFIH1, SAMHD1 ), interferon‐stimulated genes ( ISG15 and IFIF44L ) and signalling ( JAK1 ). Given the dual immune therapy, it was not possible to define whether the biological effect was related to dexamethasone or JAK inhibitor, or both.
Conclusion
Compared with natural history data, our data suggest that early diagnosis, and the use of early brain‐penetrant immune suppressants (dexamethasone), may improve outcomes in ADAR1 AGS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kids Neuroscience Centre, Faculty of Medicine and Health, The Children's Hospital at Westmead University of Sydney Sydney NSW Australia.
- Faculty of Medicine and Health, The Children's Hospital at Westmead Clinical School University of Sydney Sydney NSW Australia.
- Khoo Teck Puat-National University Children's Medical Institute National University Health System Singapore Singapore.
- Australian Genome Research Facility Ltd Westmead NSW Australia.
- Australian Genome Research Facility Ltd Melbourne VIC Australia.
- Department of Neurology The Sydney Children's Hospitals Network Sydney NSW Australia.
ORCID-Profile: Russell C Dale, Markus Hofer, Michelle Lorentzos, Shekeeb Mohammad
Zitieren
APA
Dale, R. C., Hayes, J., Han, V. X., Dissanayake, R., Lau, X., Farrar, M., Gloss, B., Hofer, M., Tantsis, E., Lorentzos, M., Abbas, S., Crow, Y. J., Mohammad, S., & Patel, S. (2026). Early brain‐penetrant immunotherapy reverses interferon signature and improves motor outcome in a case of ADAR1 ‐related Aicardi‐Goutières syndrome. Clinical & Translational Immunology, 15(7). https://doi.org/10.1002/cti2.70113
Vancouver
Dale RC, Hayes J, Han VX, Dissanayake R, Lau X, Farrar M, et al. Early brain‐penetrant immunotherapy reverses interferon signature and improves motor outcome in a case of ADAR1 ‐related Aicardi‐Goutières syndrome. Clinical & Translational Immunology. 2026;15(7). doi:10.1002/cti2.70113
BibTeX
@article{Dale2026,
author = {Dale, Russell C and Hayes, Jessica and Han, Velda X and Dissanayake, Ruwani and Lau, Xianzhong and Farrar, Michelle and Gloss, Brian and Hofer, Markus and Tantsis, Esther and Lorentzos, Michelle and Abbas, Safiyyah and Crow, Yanick J and Mohammad, Shekeeb and Patel, Shrujna},
title = {Early brain‐penetrant immunotherapy reverses interferon signature and improves motor outcome in a case of ADAR1 ‐related Aicardi‐Goutières syndrome},
journal = {Clinical & Translational Immunology},
year = {2026},
volume = {15},
number = {7},
doi = {10.1002/cti2.70113}
}
EUVIMED